Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
Seagen Inc.
Novartis
University of California, Davis
NYU Langone Health
The Methodist Hospital Research Institute
Mayo Clinic
Hoffmann-La Roche
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
University Health Network, Toronto
TILT Biotherapeutics Ltd.
Georgetown University
Genmab
H. Lee Moffitt Cancer Center and Research Institute
Pfizer
M.D. Anderson Cancer Center
Erasca, Inc.
Erasca, Inc.
Eastern Cooperative Oncology Group
Institute of Oncology Ljubljana
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Bayer
Duke University
Novartis
Memorial Sloan Kettering Cancer Center
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boehringer Ingelheim
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Replimune Inc.